Advanced Biomed (NASDAQ: ADVB) preserves Nasdaq listing after reverse split restores $1 bid

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Advanced Biomed Inc. reported that Nasdaq has determined the company regained compliance with the $1.00 per share minimum bid price requirement under Listing Rule 5550(a)(2). The company implemented a reverse stock split completed on February 20, 2026, after shareholders approved the action on January 12, 2026.

Following the reverse split, the company’s common stock maintained a closing bid of at least $1.00 per share, satisfying Nasdaq’s rule. As a result, Advanced Biomed’s stock will remain listed on The Nasdaq Stock Market, subject to a one-year Panel monitor under Listing Rule 5815(d)(4)(A).

Positive

Nasdaq compliance restored: The company regained compliance with Nasdaq Listing Rule 5550(a)(2) after its reverse stock split, so its common stock will remain listed on The Nasdaq Stock Market, preserving exchange trading status and associated liquidity.
Shareholder-approved remediation: Stockholders approved a reverse stock split on January 12, 2026, and the completed action successfully lifted the closing bid price to at least $1.00 per share, meeting the Minimum Bid Price Requirement.

Negative

Ongoing Nasdaq monitoring: The company’s shares are subject to a one-year Panel monitor under Nasdaq Listing Rule 5815(d)(4)(A), reflecting recent non-compliance and creating ongoing sensitivity to future bid-price or listing-standard issues.
Recent delisting risk history: The company did not regain compliance by the original January 14, 2026 deadline and received a delisting notice on January 16, 2026, highlighting prior sustained share-price weakness.

Insights

Advanced Biomed keeps Nasdaq listing after bid-price cure via reverse split.

Advanced Biomed Inc. faced delisting after its shares traded below the $1.00 minimum bid required by Nasdaq. The company appealed a January 2026 delisting notice and presented a remediation plan, centered on a reverse stock split approved by shareholders on January 12, 2026.

The reverse split was completed on February 20, 2026, after which the stock maintained a closing bid of at least $1.00 per share. Nasdaq’s Panel confirmed compliance with Listing Rule 5550(a)(2), allowing the shares to remain on the exchange, which helps preserve liquidity and visibility.

The listing now falls under a one-year Panel monitor pursuant to Listing Rule 5815(d)(4)(A). This oversight underscores that the company recently breached standards, and future performance relative to Nasdaq rules will be important, with any renewed shortfall potentially triggering further listing actions.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

03/16/2026 - 04:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

March 12, 2026

Date of Report (Date of earliest event reported)

Advanced Biomed Inc.

(Exact name of Company as specified in its charter)

Nevada	001-42548	87-2177170
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

No. 689-85 Xiaodong Road, Yongkang District

Tainan City, Taiwan

(Address of principal executive offices)

886-6-3121716

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		ADVB		The Nasdaq Stock Market LLC

Item 8.01 Other Event

As previously disclosed, on July 18, 2025, Advanced Biomed Inc. (the “Company”) received a written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq” or the “Staff”) notifying the Company that the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a compliance period of 180 calendar days, or until January 14, 2026, to regain compliance with the Minimum Bid Price Requirement.

The Company did not regain compliance with the Minimum Bid Price Requirement by January 14, 2026. Accordingly, by letter dated January 16, 2026, the Staff notified the Company that its securities would be scheduled for delisting from Nasdaq and suspended at the opening of business on January 27, 2026, unless the Company requested an appeal of this determination before a Nasdaq Listing Qualifications Hearings Department (the “Panel”).

On January 21, 2026, the Company appealed the Staff’s delisting determination by submitting a hearing request to the Panel, which stayed the suspension of the Company’s securities and the filing of a Form 25-NSE pending the Panel’s decision. A hearing was held on February 17, 2026. The Company presented to the Panel a plan to regain compliance with the Minimum Bid Price Requirement, including the implementation of a reverse stock split approved by the Company’s stockholders on January 12, 2026.

On March 12, 2026, the Company received a written decision from the Panel stating that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2). The Panel determined that, following the Company’s reverse stock split completed on February 20, 2026, the Company had maintained a closing bid price of $1.00 or more per share, and therefore the Company is in compliance with the Minimum Bid Price Requirement. As a result, the Company’s common stock will remain listed on The Nasdaq Stock Market, subject to a one-year Panel monitor pursuant to Nasdaq Listing Rule 5815(d)(4)(A).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Advanced Biomed Inc.

Date: March 16, 2026	By:	/s/ Yi Lu
		Yi Lu
		Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Advanced Biomed Inc. (ADVB) announce regarding its Nasdaq listing status?

Advanced Biomed Inc. announced that Nasdaq’s Listing Panel determined the company has regained compliance with the $1.00 minimum bid price rule. As a result, ADVB’s common stock will remain listed on The Nasdaq Stock Market, avoiding the previously threatened delisting.

How did Advanced Biomed Inc. (ADVB) regain compliance with Nasdaq’s $1.00 minimum bid price requirement?

Advanced Biomed regained compliance by implementing a shareholder-approved reverse stock split completed on February 20, 2026. After this split, the company’s stock maintained a closing bid of at least $1.00 per share, satisfying Nasdaq Listing Rule 5550(a)(2).

Was Advanced Biomed Inc. (ADVB) at risk of being delisted from Nasdaq?

Yes. After failing to meet the $1.00 minimum bid price by January 14, 2026, ADVB received a Nasdaq delisting notice on January 16, 2026. The company appealed, obtained a hearing, and ultimately avoided delisting by restoring compliance.

What ongoing conditions apply to Advanced Biomed Inc.’s (ADVB) Nasdaq listing after regaining compliance?

Advanced Biomed’s stock remains listed but is subject to a one-year Panel monitor under Nasdaq Listing Rule 5815(d)(4)(A). This means Nasdaq will closely observe continued compliance with listing standards following the recent bid-price deficiency.

When did Advanced Biomed Inc. (ADVB) complete its reverse stock split to support Nasdaq compliance?

The company completed its reverse stock split on February 20, 2026. This action followed shareholder approval on January 12, 2026 and subsequently allowed the stock to maintain a closing bid price of at least $1.00 per share.

Why did Advanced Biomed Inc. (ADVB) request a Nasdaq hearing?

Advanced Biomed requested a hearing on January 21, 2026 to appeal Nasdaq’s delisting notice. The hearing, held on February 17, 2026, allowed the company to present its reverse stock split plan and ultimately secure a favorable compliance decision.

Filing Exhibits & Attachments

3 documents